Potential use of protease inhibitors as vaginal and colorectal microbicides

Current HIV Research

Volumn 10, Issue 1, 2012, Pages 42-52

  Herrera, Carolina ^a   Shattock, Robin J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Darunavir; HIV 1; Lopinavir; Microbicides; Protease inhibitors; Ritonavir; Saquinavir; Tissue explants

Indexed keywords

DARUNAVIR; LOPINAVIR; MICROBICIDE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CELL PROLIFERATION; DIARRHEA; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; MOUTH MUCOSA; NONHUMAN; PROTEIN BINDING; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS REPLICATION;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, RECTAL; ANTI-INFECTIVE AGENTS, LOCAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; VIRUS REPLICATION;

EID: 84857125406     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212799304607     Document Type: Article

References (138)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329(5996):1168-1174.
2. Shattock RJ, Warren M, McCormack S, Hankins CA. AIDS. Turning the tide against HIV. Science 2011; 333(6038): 42-43.
3. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother 2009; 53(5): 1797-1807.
4. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. Aids 2011; 25: 1971-1979.
5. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85(13): 4686-4690.
6. Jacks T, Power MD, Masiarz FR, et al. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 1988; 331(6153): 280-283.
7. Lapatto R, Blundell T, Hemmings A, et al. X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes. Nature 1989; 342(6247): 299-302.
8. Navia MA, Fitzgerald PM, McKeever BM, et al. Threedimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989; 337(6208): 615-620.
9. Wlodawer A, Miller M, Jaskolski M, et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989; 245(4918): 616-21.
10. Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 2002; 10(3): 369-81.
11. Pettit SC, Gulnik S, Everitt L, Kaplan AH. The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage. J Virol 2003; 77(1): 366-74.
12. Pettit SC, Moody MD, Wehbie RS, et al. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 1994; 68(12): 8017-27.
13. Pettit SC, Sheng N, Tritch R, et al. The regulation of sequential processing of HIV-1 Gag by the viral protease. Adv Exp Med Biol 1998; 436: 15-25.
14. Speck RR, Flexner C, Tian CJ, Yu XF. Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrob Agents Chemother 2000; 44(5): 1397-1403.
15. Wiegers K, Rutter G, Kottler H, et al. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol 1998; 72(4): 2846-2854.
16. Pettit SC, Everitt LE, Choudhury S, Dunn BM, Kaplan AH. Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J Virol 2004; 78(16): 8477-8485.
17. Mervis RJ, Ahmad N, Lillehoj EP, et al. The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors. J Virol 1988; 62(11): 3993-4002.
18. Kaplan AH, Zack JA, Knigge M, et al. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol 1993; 67(7): 4050-4055.
19. Ross EK, Fuerst TR, Orenstein JM, et al. Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease. AIDS Res Hum Retroviruses 1991; 7(5): 475-483.
20. Rivero A, Perez-Camacho I. Does lopinavir/ritonavir alter the primary gingival epithelium? Expert Rev Anti Infect Ther 2010; 8(12): 1345-1349.
21. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75(16): 7462-7469.
22. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2(7):760-766.
23. Knechten H, Stephan C, Mosthaf FA, et al. The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients. Eur J Med Res 2011; 16(3): 93-100.
24. Nisole S, Saib A. Early steps of retrovirus replicative cycle. Retrovirology 2004; 1: 9.
25. Tozser J, Shulenin S, Kadas J, et al. Human immunodeficiency virus type 1 capsid protein is a substrate of the retroviral proteinase while integrase is resistant toward proteolysis. Virology 2003; 310(1): 16-23.
26. Donahue DA, Sloan RD, Kuhl BD, et al. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother 2010; 54(3): 1047-1054.
27. Keele BF, Derdeyn CA. Genetic and antigenic features of the transmitted virus. Curr Opin HIV AIDS 2009; 4(5): 352-357.
28. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011; 62: 127-139.
29. Li Q, Estes JD, Schlievert PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458(7241): 1034-1038.
30. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10(1): 11-23.
31. Fischetti L, Barry SM, Hope TJ, Shattock RJ. HIV-1 infection of human penile explant tissue and protection by candidate microbicides. Aids 2009; 23(3): 319-328.
32. Fletcher PS, Elliott J, Grivel JC, et al. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. Aids 2006; 20(9): 1237-1245.
33. Hu Q, Frank I, Williams V, et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004; 199(8): 1065-1075.
34. Craig JC, Duncan IB, Hockley D, et al. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991; 16(4): 295-305.
35. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 248(4953): 358-361.
36. Martin JA, Mobberley MA, Redshaw S, et al. The inhibitory activity of a peptide derivative against the growth of simian immunodeficiency virus in C8166 cells. Biochem Biophys Res Commun 1991; 176(1): 180-188.
37. Martin JA. Ro 31-8959/003. Drugs Future 1991; 16(3).
38. Williams PEO, Muirhead GJ, Madigan MJ, Mitchell AM, Shaw T. Disposition and bioavailability of the HIVproteinase inhibitor, Ro 31-8959, after single doses in healthy volunteers. Br J Clin Pharmacol 1992; 34(2): 155P-156P.
39. Muirhead GJ, Shaw T, Williams PEG, et al. Pharmacokinetics of the HIV-proteinase inhibitor, Ro 318959, after single and multiple oral doses in healthy volunteers. Br J Clin Pharmacol 1992; 34(2): 170P-171P.
40. Protease inhibitors--an update. Crit Path AIDS Proj 1994; (No 30): 26-28.
41. Connell EV, Hsu MC, Richman DD. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. Antimicrob Agents Chemother 1994; 38(2): 348-352.
42. Johnson VA, Merrill DP, Chou TC, Hirsch MS. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis 1992; 166(5): 1143-1146.
43. Roberts NA, Craig JC, Duncan IB. HIV proteinase inhibitors. Biochem Soc Trans 1992; 20(2): 513-6.
44. Jacobsen H, Haenggi M, Ott M, et al. Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Antiviral Res 1996; 29(1): 95-97.
45. Huff JR, Kahn J. Discovery and clinical development of HIV-1 protease inhibitors. Adv Protein Chem 2001; 56: 213-251.
46. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A 1995; 92(7): 2484-2488.
47. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373(6510): 123-126.
48. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N3Engl J Med 1995; 333(23): 1534-1539.
49. Mathez D, Bagnarelli P, Gorin I, et al. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Antivir Ther 1997; 2(3): 175-183.
50. Notermans DW, Jurriaans S, de Wolf F, et al. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group. Aids 1998; 12(2): 167-173.
51. Markowitz M, Mo H, Kempf DJ, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995; 69(2): 701-706.
52. Schmit JC, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). Aids 1996; 10(9): 995-999.
53. Norvir prescribing information AL, IL 60064, USA Ref no. 03- A359-R4-Rev. April 2010.
54. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277(1): 423-431.
55. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003; 36(12): 1585-1592.
56. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997; 41(3): 654-660.
57. Carrillo A, Stewart KD, Sham HL, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72(9): 7532-7541.
58. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42(12): 3218-3224.
59. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189(1): 51-60.
60. Conradie F, Sanne I, Venter W, Eron J. Failure of lopinavirritonavir (Kaletra)-containing regimen in an antiretroviral-naïve patient. Aids 2004; 18(7): 1084-1085.
61. Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. Aids 2004; 18(14): 1965-1966.
62. Masquelier B, Breilh D, Neau D, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002; 46(9): 2926-2932.
63. Nijhuis M, Wensing AM, Bierman WF, et al. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. J Infect Dis 2009; 200(5): 698-709.
64. Romano L, Peduzzi C, Venturi G, et al. Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice. J Acquir Immune Defic Syndr 2002; 30(5): 533-535.
65. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63(8): 769-802.
66. Kaletra prescribing information AL, IL 60064, USA Ref no. 03- A465-R10-Rev. February 2011.
67. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49(6): 2314-2321.
68. Koh Y, Nakata H, Maeda K, et al. Novel bistetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003; 47(10): 3123-3129.
69. Curran A, Gutirerrez M, Deig E, et al. Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. J Antimicrob Chemother; 65(10): 2195-2203.
70. Prezista prescribing information TI. December 2010.
71. King NM, Prabu-Jeyabalan M, Nalivaika EA, et al. Structural and thermodynamic basis for the binding of TMC114, a nextgeneration human immunodeficiency virus type 1 protease inhibitor. J Virol 2004; 78(21): 12012-12021.
72. De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatmentexperienced patients. Aids 2009; 23(14): 1829-1840.
73. de Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008; 24(3): 379-388.
74. Bennett DE, Zaidi I, Heneine W, et al. Prevalence of mutations associated with antiretroviral drug resistance among men and women newly diagnosed with HIV in 10 US cities, 1997-2001. Antiviral Therapy 2003; 8(Supplement 1): S133.
75. Briones C, Perez-Olmeda M, Rodriguez C, et al. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr 2001; 26(2): 145-150.
76. Chaix M, Descamps D, Mouajjah S, et al. French National Sentinel Survey of antiretroviral resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. Antiviral Therapy 2003; 8(Supplement 1): S137.
77. Duwe S, Brunn M, Altmann D, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 2001; 26(3): 266-273.
78. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347(6): 385-394.
79. Mendoza C, Rodriguez C, Corral A, et al. Evidence for a different transmission efficiency of viruses with distinct drug-resistance genotypes. Antiviral Therapy 2003; 8(Supplement 1): S144.
80. Resistance UCGoMtToHD. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. Bmj 2001; 322(7294): 1087-1088.
81. Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. Aids 2000; 14(2): F17-F23.
82. Ala PJ, Huston EE, Klabe RM, et al. Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. Biochemistry 1998; 37(43): 15042-15049.
83. Ala PJ, Huston EE, Klabe RM, et al. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 1997; 36(7): 1573-1580.
84. Chen Z, Li Y, Schock HB, et al. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J Biol Chem 1995; 270(37): 21433-21436.
85. Mahalingam B, Louis JM, Hung J, Harrison RW, Weber IT. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins 2001; 43(4): 455-464.
86. Mahalingam B, Louis JM, Reed CC, et al. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur J Biochem 1999; 263(1): 238-245.
87. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002; 15(2): 247-277.
88. Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002; 76(21): 11104-11112.
89. Erickson JW, Gulnik SV, Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. Aids 1999; 13 Suppl A: S189-S204.
90. Muzammil S, Ross P, Freire E. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 2003; 42(3): 631-638.
91. Xie D, Gulnik S, Gustchina E, et al. Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH. Protein Sci 1999; 8(8): 1702-1707.
92. Scott WR, Schiffer CA. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure 2000; 8(12): 1259-1265.
93. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. Aids 2007; 21(2): 215-223.
94. Hertogs K, Bloor S, Kemp SD, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. Aids 2000; 14(9): 1203-1210.
95. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002; 185(5): 599-607.
96. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358(20): 2095-2106.
97. Soulie C, Assoumou L, Ghosn J, et al. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. Aids 2009; 23(12): 1605-1608.
98. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. Aids 2007; 21(14): 1899-1907.
99. Min SS, Corbett AH, Rezk N, et al. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr 2004; 37(5): 1577-1580.
100. Patterson K, Jennings S, Falcon R, Mrus J, Kashuba A. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother 2011; 55(3): 1120-1122.
101. Salas Herrera IG, Pearson RM, Turner P. Quantitation of albumin and alpha-1-acid glycoprotein in human cervical mucus. Hum Exp Toxicol 1991; 10(2): 137-139.
102. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146(8): 591-601.
103. Nicol MR, Kashuba AD. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther 2010; 88(5): 598-609.
104. Gill MJ. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team. Aids 1998; 12(11): 1400-1402.
105. Fortovase prescribing information RP, RLI, 340 Kingsland Street, Nutley, NJ 07110, USA. December 2003.
106. Viracept prescribing information A, CA 92037, USA. Item no. 634200MV, Item # 634200MV. May 2009.
107. Bode H, Lenzner L, Kraemer OH, et al. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells. Antivir Ther 2005; 10(5): 645-655.
108. Bode H, Schmidt W, Schulzke JD, et al. Effects of HIV protease inhibitors on barrier function in the human intestinal cell line HT- 29/B6. Ann N Y Acad Sci 2000; 915: 117-122.
109. Bode H, Schmidt W, Schulzke JD, et al. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir but not indinavir impair the epithelial barrier in the human intestinal cell line HT-29/B6. Aids 1999; 13(18): 2595-2597.
110. Wu X, Sun L, Zha W, et al. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology 2010; 138(1): 197-209.
111. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007; 44(5): 493-499.
112. Israr M, Mitchell D, Alam S, et al. The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium. HIV Med 2010; 12(3): 145-156.
113. Israr M, Mitchell D, Alam S, et al. Effect of the HIV protease inhibitor amprenavir on the growth and differentiation of primary gingival epithelium. Antivir Ther 2010; 15(2): 253-265.
114. Danaher RJ, Wang C, Roland AT, et al. HIV protease inhibitors block oral epithelial cell DNA synthesis. Arch Oral Biol 2010; 55(2): 95-100.
115. Danaher RJ, Kaetzel CS, Greenberg RN, et al. HIV protease inhibitors alter innate immune response signaling to doublestranded RNA in oral epithelial cells: implications for immune reconstitution inflammatory syndrome? Aids 2010; 24(16): 2587-2590.
116. Lei B, Zha W, Wang Y, et al. Development of a novel selfmicroemulsifying drug delivery system for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction. Mol Pharm 2010; 7(3): 844-853.
117. Garg S, Goldman D, Krumme M, et al. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res 2010; 88 Suppl 1: S19-S29.
118. Ndesendo VM, Pillay V, Choonara YE, et al. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS PharmSciTech 2008; 9(2): 505-520.
119. Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res 2010; 88 Suppl 1: S55-S66.
120. Brouwers J, Vermeire K, Grammen C, Schols D, Augustijns P. Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: A case study with saquinavir. Antiviral Res 2011; 91(2): 217-223.
121. Majumdar A, Wankhade G, Kamble PD, Harinath BC. Effect of HIV protease inhibitors and Orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis. Indian J Tuberc 2011; 58(1): 4-10.
122. Mastrolorenzo A, Rusconi S, Scozzafava A, Barbaro G, Supuran CT. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr Med Chem 2007; 14(26):2734-2748.
123. Bruning A, Gingelmaier A, Friese K, Mylonas I. New prospects for nelfinavir in non-HIV-related diseases. Curr Mol Pharmacol 2010; 3(2): 91-97.
124. Frohoff C, Moodley M, Fairlie L, et al. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One 2011; 6(2): e17273.
125. McIlleron H, Ren Y, Nuttall J, et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther 2011; 16(3): 417-421.
126. Li Y, Qin L, Peng N, et al. Antimalarial effects of human immunodeficiency virus protease inhibitors in rhesus macaques. Antimicrob Agents Chemother 2011; 55(6): 3039-3042.
127. Nsanzabana C, Rosenthal PJ. In vitro activity against Plasmodium falciparum of antiretroviral drugs. Antimicrob Agents Chemother 2011; 55(11): 5073-5077.
128. Bektic J, Lell CP, Fuchs A, et al. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. FEMS Immunol Med Microbiol 2001; 31(1): 65-71.
129. Cassone A, De Bernardis F, Torosantucci A, et al. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180(2): 448-453.
130. Federico M. HIV-protease inhibitors block the replication of both vesicular stomatitis and influenza viruses at an early post-entry replication step. Virology 2011; 417(1): 37-49.
131. Hobday TJ, Goldberg RM. Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer. Clin Colorectal Cancer 2002; 2(3): 161-169.
132. Gills JJ, Lopiccolo J, Dennis PA. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. Autophagy 2008; 4(1): 107-109.
133. Gills JJ, Lopiccolo J, Tsurutani J, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13(17): 5183-5194.
134. Bruning A, Vogel M, Mylonas I, Friese K, Burges A. Bortezomib Targets the Caspase-Like Proteasome Activity in Cervical Cancer Cells, Triggering Apoptosis That Can be Enhanced by Nelfinavir. Curr Cancer Drug Targets 2011; 11(7): 799-809.
135. Hampson L, Kitchener HC, Hampson IN. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther 2006; 11(6): 813-825.
136. Kim DH, Jarvis RM, Allwood JW, et al. Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells. Anal Bioanal Chem 2010; 398(7-8): 3051-3061.
137. Kim DH, Jarvis RM, Xu Y, et al. Combining metabolic fingerprinting and footprinting to understand the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral drug lopinavir. Analyst 2010; 135(6):1235-1244.
138. Galani E, Christodoulou C. Human papilloma viruses and cancer in the post-vaccine era. Clin Microbiol Infect 2009; 15(11): 977-981.